NVCR

NovoCure Limited

21.36 USD
+0.02 (+0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

NovoCure Limited stock is down -2.86% since 30 days ago. The next earnings date is Jul 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
21 May 15:16 21 Jun, 2024 25.00 PUT 281 210
21 May 17:25 21 Jun, 2024 25.00 PUT 196 210
22 May 18:28 21 Jun, 2024 15.00 CALL 38 326
30 May 15:17 21 Jun, 2024 22.50 CALL 330 852
31 May 15:46 21 Jun, 2024 22.50 CALL 370 1404
03 Jun 15:40 21 Jun, 2024 25.00 PUT 353 1212
03 Jun 19:42 21 Jun, 2024 20.00 CALL 74 507
04 Jun 15:08 21 Jun, 2024 25.00 PUT 200 1610
05 Jun 19:38 21 Jun, 2024 25.00 CALL 915 1832
07 Jun 17:32 17 Jan, 2025 15.00 CALL 54 1072

About NovoCure Limited

NovoCure Limited engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma.